Cover Image
市場調查報告書

萊姆病:開發平台評估

Lyme Disease - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 200465
出版日期 內容資訊 英文 35 Pages
訂單完成後即時交付
價格
Back to Top
萊姆病:開發平台評估 Lyme Disease - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 35 Pages
簡介

萊姆病或稱萊姆關節炎,是由蜱傳播給人類的細菌所引起的感染性疾病,其症狀包括有高熱、頭痛、筋骨酸痛、全身抽搐以及紅疹,因此又稱之為萊姆關節炎。致病因子有年齡、性別、地區等。治療法有服用抗生素。

本報告涵蓋全球萊姆病治療藥的開發平台資料,提供目前開發平台狀況和最新趨勢,藥物簡介,再加上主要企業及他們正開發中的產品評估等,為您概述為以下內容。

目錄

簡介

  • 分析範圍

萊姆病概要

治療藥的開發

  • 萊姆病開發中產品:概要
  • 萊姆病開發中產品:比較分析

萊姆病:正在開發的治療藥:各企業

萊姆病:正在開發的治療藥:大學·研究機關別

萊姆病:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

萊姆病:開發中的產品:各企業

萊姆病:開發中的產品:大學·研究機關別

萊姆病:治療藥的開發企業

  • Baxter International Inc.
  • VG Life Sciences, Inc.
  • Valneva SE

萊姆病:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各類型分子

藥物簡介

  • 阿奇霉素凝膠
  • Multivalent Recombinant OspA Lyme Borreliosis Vaccine
  • IC-15
  • VGV-L
  • Ixolaris
  • Isac
  • doxorubicin Nanosphere
    • 產品概要
    • 作用機制
    • R&D的進展

萊姆病:最近的開發平台趨勢

萊姆病:暫停中的計劃

萊姆病:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8238IDB

Summary

Global Markets Direct's, 'Lyme Disease - Pipeline Review, H2 2016', provides an overview of the Lyme Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Lyme Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lyme Disease and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Lyme Disease
  • The report reviews pipeline therapeutics for Lyme Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Lyme Disease therapeutics and enlists all their major and minor projects
  • The report assesses Lyme Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Lyme Disease

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Lyme Disease
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Lyme Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Lyme Disease Overview
  • Therapeutics Development
    • Pipeline Products for Lyme Disease - Overview
  • Lyme Disease - Therapeutics under Development by Companies
  • Lyme Disease - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Lyme Disease - Products under Development by Companies
  • Lyme Disease - Companies Involved in Therapeutics Development
    • LondonPharma Ltd
    • NovoBiotic Pharmaceuticals, LLC
    • Valneva SE
  • Lyme Disease - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • azithromycin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lyme disease vaccine 2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Nu-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Lyme Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Lyme Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VLA-15 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Lyme Disease - Dormant Projects
  • Lyme Disease - Product Development Milestones
    • Featured News & Press Releases
      • Mar 24, 2016: VALNEVA to present at the 16th World Vaccine Congress in Washington D.C.
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Lyme Disease, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Lyme Disease - Pipeline by LondonPharma Ltd, H2 2016
  • Lyme Disease - Pipeline by NovoBiotic Pharmaceuticals, LLC, H2 2016
  • Lyme Disease - Pipeline by Valneva SE, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Lyme Disease - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Lyme Disease, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top